Drug Treatment of Overactive Bladder: Efficacy, Cost and Quality-of-Life Considerations

ISSN： 0012-6667

Source： Drugs, Vol.64, Iss.15, 2004-01, pp. : 1643-1656

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Breast Cancer Management: Quality-of-Life and Cost Considerations

By Radice D. Redaelli A.

PharmacoEconomics, Vol. 21, Iss. 6, 2003-01 ,pp. : 383-396

Adis International

Access to resources Recommend Favorite

Evidence for the efficacy and safety of tolterodine in the treatment of overactive bladder

By Abrams Paul

Expert Opinion on Pharmacotherapy, Vol. 2, Iss. 10, 2001-10 ,pp. : 1685-1701

Informa Healthcare

Access to resources Recommend Favorite

Disease Burden of Overactive Bladder: Quality-of-Life Data Assessed Using ICI-Recommended Instruments

By Basra Ramandeep Kelleher Con

PharmacoEconomics, Vol. 25, Iss. 2, 2007-01 ,pp. : 129-142

Adis International

Access to resources Recommend Favorite

Therapeutic Options in the Treatment of Multiple Myeloma: Pharmacoeconomic and Quality-of-Life Considerations

By Wisløff F.

PharmacoEconomics, Vol. 16, Iss. 4, 1999-10 ,pp. : 329-341

Adis International

Access to resources Recommend Favorite

Quality-of-Life Considerations in the Treatment of Early-Stage Breast Cancer in the Elderly

By Reimer Toralf Gerber Bernd

Drugs & Aging, Vol. 27, Iss. 10, 2010-10 ,pp. : 791-800

Adis International

Access to resources Recommend Favorite